NORD and 88 patient organizations send letter to Congressional leaders urging them to improve clinical trial diversity as part of PDUFA reauthorization
Published: May 11, 2022
Tagged in: User Fee Act
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD and 88 patient organizations send letter to Congressional leaders urging them to improve clinical trial diversity as part of PDUFA reauthorization
Published: May 11, 2022
Tagged in: User Fee Act
NORD submits a statement for the record on H.R. 7667, the Food and Drug Amendments of 2022.
Published: May 11, 2022
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
NORD submits a statement for the record to the Senate Committee on Health, Education, Labor and Pension regarding the FDA’s user fee agreements
Published: Apr 5, 2022
Tagged in: User Fee Act, FDA’s Accelerated Approval Pathway, Advancing Rare Disease Research and Regulatory Science
NORD and 90 organizations representing patients with rare diseases call on HHS to strengthen and improve the Accelerated Approval pathway
Published: Apr 4, 2022
Tagged in: User Fee Act
NORD and 90 organizations representing patients with rare diseases call on Congress to strengthen the Accelerated Approval pathway as part of PDUFA reauthorization
Published: Apr 4, 2022
Tagged in: User Fee Act